Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wei Zhang
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically or cytologically confirmed metastatic colorectal cancer who have measurable metastatic disease according to the Resolute Efficacy Criteria for Solid Tumors (RECIST) version 1.1.
Received standard second-line therapy, achieved stable disease(SD) and above by recist1.1 tumor assessment and maintained for 3 months.
Eastern Oncology Collaborative Group(ECOG) physical status of 0 or 1 at trial entry and life expectancy ≥ 3 months.
No bone marrow suppression and normal heart, lung, liver and kidney function.
Voluntary participation in research.
You may not be if
Concurrent primary tumors of other types.
MSI-H/dMMR type mCRC patients.
Heart, liver, kidney, bone marrow insufficiency or mental abnormalities.
Intolerant to treatment methods
Concurrent participants in other clinical trials.
Pregnant or lactating women.
Patients deemed unsuitable for study participation by the remaining investigators.
Clareo Health | Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
